Control of cardiovascular risk factors and health behaviors in patients post acute coronary syndromes eligible for protein convertase subtilisin/kexin-9 inhibitors.

Details

Serval ID
serval:BIB_E32FC1F9E616
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Control of cardiovascular risk factors and health behaviors in patients post acute coronary syndromes eligible for protein convertase subtilisin/kexin-9 inhibitors.
Journal
International journal of cardiology
Author(s)
Butty A., Gencer B., Koskinas K.C., Carballo D., Räber L., Klingenberg R., Matter C.M., Lüscher T.F., Windecker S., Muller O., Rodondi N., Mach F., Nanchen D.
ISSN
1874-1754 (Electronic)
ISSN-L
0167-5273
Publication state
Published
Issued date
15/01/2020
Peer-reviewed
Oui
Volume
299
Pages
289-295
Language
english
Notes
Publication types: Journal Article
Publication Status: ppublish
Abstract
We aimed to examine cardiovascular risk factors and health behaviors in patients with acute coronary syndromes (ACS) according to potential extension of eligibility criteria for protein convertase subtilisin/kexin-9 inhibitors (PCSK9i) to all patients with low-density lipoprotein cholesterol (LDL-c) equal or above 1.8 mmol/l.
In this prospective cross-sectional study, patients with ACS between 2009 and 2016 and with available LDL-c at one year were considered. We defined three mutually exclusive groups of patients according to eligibility for PCSK9i: "not eligible", "currently eligible", and "newly eligible". We explored the control of cardiovascular risk factors and health behaviors.
Out of 3025 patients who had an ACS one year ago, 1071 (35.4%) were not eligible for PCSK9i, 415 (13.7%) were currently eligible, and 1539 (50.9%) were newly eligible. The proportion of patients with uncontrolled hypertension in the not eligible group was lower than in the group currently eligible (27.6% vs 33.6%, p = 0.02), but similar to the group newly eligible (27.6% vs 28.2%, p = 0.73). The proportion of smokers in the not eligible group was lower than in the group currently eligible (21.2% vs 28.0%, p = 0.02), but similar to the group newly eligible (21.2% vs 22.5%, p = 0.51).
More than half of patients with ACS would be additionally eligible for PCSK9i if prescription is extended from current guidelines to all patients with LDL-c equal or above 1.8 mmol/l. Patients currently eligible for PCSK9i one year after an ACS had a worst control of cardiovascular risk factors than patients potentially newly eligible.
Keywords
Acute coronary syndromes, Cardiovascular disease, Cardiovascular prevention, Low-density lipoprotein cholesterol, Protein convertase subtilisin/kexin-9 inhibitors
Pubmed
Web of science
Create date
03/11/2019 0:09
Last modification date
03/02/2021 7:26
Usage data